Pfizer sees weaker 2026 due to lower Covid-19 sales

(Sharecast News) - American pharmaceutical giant Pfizer expects revenues and profits to slip slightly in 2026, partly as a result of lost revenues from its Covid-19 products. In an analyst and investor call on Tuesday, the company said it was revising its 2025 revenue guidance to $62.0bn, slightly below the mid-point of its previous guidance of $61bn-64bn. Earnings per share are tipped to come in at $3.00-3.15.

Current consensus forecasts are for revenues of $62.5bn and EPS of $3.13.

For 2026, Pfizer said revenues would be in the range of $59.5-62.5bn, the mid-point of which represents a $1bn decline from 2025.

Revenues from Covid-19 products are now expected to be $1.5bn lower than what was expected in 2025, while the company will be hit by $1.5bn from the loss of exclusivity (LOE) on certain products. Excluding both Covid-19 and LOE products, operational revenue growth is forecast to be around 4% in 2026.

As for profits, the company pointed to 2026 EPS of $2.80-3.00.

"2025 was a year of strong execution and strategic progress for Pfizer," said chief executive Albert Bourla.

"We've strengthened our foundation, advanced our R&D pipeline and positioned our company for sustainable growth in the post-LOE period. As we move into 2026, we're focused on serving patients with innovative medicines and vaccines while creating long-term value for our shareholders."

Pfizer's stock was down 3.2% at $25.59 by 1512 GMT.